Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

5 February 2025 - The medicine is already approved in the UK to treat advanced cases of the disease. ...

Read more →

Nemolizumab approved to treat prurigo nodularis and atopic dermatitis for patients in the UK

17 February 2025 - This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure. ...

Read more →

Efanesoctocog alfa approved to prevent and treat bleeding in children and adults with severe or moderate haemophilia A

14 February 2025 - The MHRA has today approved efanesoctocog alfa (Altuvoct) to be used to treat and prevent bleeding in ...

Read more →

Medical imaging agent gozetotide approved for diagnosis of prostate cancer

12 February 2025 - Gozetotide binds to the cancer cells with prostate-specific membrane antigen on their surface, making them visible during ...

Read more →

Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy

12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...

Read more →

NICE joins international collaboration on HTA methods research

12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)

12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...

Read more →

Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder

12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...

Read more →

Nivolumab and ipilimumab for the first-line treatment of patients with metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Izchiq vaccine approved to protect adults against Chikungunya

4 February 2025 - The MHRA has today approved the vaccine chikungunya vaccine (live) (Ixchiq) to protect adults against chikungunya disease, ...

Read more →

Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)

5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...

Read more →

Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)

5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...

Read more →

Comanche Biopharma awarded Innovation passport designation by the UK Innovative Licensing and Access Pathway Steering Group for CBP-4888, an investigational siRNA drug candidate for the treatment of sFlt1-mediated preterm pre-eclampsia

30 January 2025 - A novel investigational drug candidate, CBP-4888 leverages the precise targeting ability of siRNAs to downregulate sFlt1 ...

Read more →

Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma

4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →